Exelixis reported $658.69M in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 342M 34.04M Sep/2026
Agios Pharmaceuticals USD 55.38M 10.64M Sep/2026
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
Amgen USD 10.4B 300M Sep/2026
AstraZeneca USD 16.21B 830M Sep/2026
Bayer EUR 10.05B 820M Sep/2026
BioMarin Pharmaceutical USD 1.03B 40M Sep/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Cytokinetics USD 47.6M 19M Sep/2026
Eisai JPY 235.63B 1.3B Sep/2026
Eli Lilly USD 24.4B 1.43B Sep/2026
Exelixis USD 658.69M 30M Sep/2026
Genmab DKK 1.16B 259M Jun/2026
Glaxosmithkline GBP 8.89B 1.2B Sep/2026
Incyte USD 1.56B 110M Sep/2026
Ionis Pharmaceuticals USD 243M 25M Sep/2026
MacroGenics USD 32.83M 12.03M Jun/2026
Merck USD 18.1B 1.5B Sep/2026
Moderna USD 1.31M 98.69M Sep/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 1.12B 161M Sep/2026
Novartis USD 14.52B 112M Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Sanofi EUR 12.3B 160M Jun/2026
Takeda JPY 1.19T 32.9B Sep/2026
Ultragenyx Pharmaceutical USD 173M 41M Sep/2026
Xencor USD 116.52M 65.3M Sep/2026